Warning
Lupin Pharmaceuticals Inc. Recalls Liraglutide Injection
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0541-2026Drug / Pharmaceutical
Lupin Pharmaceuticals Inc. Recalls Liraglutide Injection
Lupin Pharmaceuticals Inc. · Class II — Moderate Risk
Product Description
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.
Reason for Recall
Presence of particulate matter: a white thread-like structure in the cartridge
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide within U.S
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Lupin Pharmaceuticals Inc. has recalled a pharmaceutical product that the FDA classified as Class II affecting 217,621 pen injectors. The recall was initiated on April 24, 2026. Presence of particulate matter: a white thread-like structure in the cartridge. It was distributed nationwide. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.